Participated · Series A · Nov 2019

Cadence Neuroscience develops a neuromodulation therapy that uses chronic subthreshold cortical stimulation to modulate EEG biomarkers and reduce or eliminate seizures. The therapy is based on research from a Mayo Clinic neurology and neurosurgery team led by Gregory Worrell, M.D., Ph.D. Cadence is clinical‑stage and intends to use the new funding to complete pivotal clinical studies and pursue FDA clearance. The company is led by CEO Kent Leyde and was founded in 2017. It is based in Redmond, WA and focuses on treating both pediatric and adult patients with focal drug‑resistant epilepsy. Cadence recently closed a Series B financing to advance its clinical program. Cadence Neuroscience is an early-stage medical device company founded in 2017 by Kent Leyde and based in Redmond, Wash. Its core technology was developed at Mayo Clinic’s Rochester campus and is currently under clinical evaluation. The company is developing a therapy that uses chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures; the approach was developed by a Mayo Clinic neurology and neurosurgery team led by Gregory Worrell, Mathew Stead, Brian Lundstrom, Ben Brinkmann and Jamie VanGompel. Cadence plans to use new funding to further develop the technology, conduct clinical studies, and pursue FDA approval. The company focuses on therapies for epilepsy and other neurological disorders and remains in early clinical and development stages.

Led · Equity · Nov 2009

NeuroTherapeutics Pharma is a Chicago-based biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company develops compounds that act through a specific mechanism of action; its lead molecule is NTP-2014. These compounds have potential application across multiple diseases, including epilepsy, pain and other CNS indications. NeuroTherapeutics closed a $43M Series B financing to fund its programs. The new capital will enable advancement of NTP-2014 up to and through multiple proof-of-concept Phase II trials and support further development of a pipeline to expand this new class of therapy. As part of the financing, two investors’ representatives—Luke Evnin of MPM Capital and Elaine Jones of Pfizer Venture Investments—will join the company’s board of directors. NeuroTherapeutics Pharma, based in Chicago, IL, focuses on developing novel therapies for central nervous system disorders. Its lead program is NTP-2014, which the company plans to advance through multiple proof-of-concept Phase II trials. The company intends to further develop a pipeline to expand this new class of therapy. NeuroTherapeutics is backed by Novo Ventures and Thomas, McNerney and Partners and is currently raising a Series B financing to support development. Recently it received a $100,000 investment from the Epilepsy Therapy Project. The Series B is intended to advance NTP-2014 through Phase II trials and fund broader pipeline development.